Floatz logo

Inno-206

Dyslipidemia

Cancer center Stefan Kukura Hospital MichalovceActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Dyslipidemia cohort.

Asset / SponsorPhaseRating
Lipitor
Johns Hopkins University
Phase 4A
Rosuvastatin
Korea University Anam Hospital
Phase 4A
SIMVASTATIN
Eli Lilly and Company
Phase 4BBB
Fenofibrate
Lewai Sharki Abdulaziz, MSc PhD
Phase 4BBB
ADVICOR COMPONENT NIACIN
University of Hawaii
Phase 4BBB

View all 27 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →